Mustang Bio, Inc. (MBIO) · Oct 15, 2026 · Other events

Mustang Bio Nasdaq extension buys time as reverse split looms

Nasdaq grace period — Compliance deadline extended to April 12, 2027

Mustang Bio won a six-month Nasdaq compliance extension after missing the $1 bid-price deadline, keeping its listing alive but raising reverse-split risk.

Mustang Bio is a clinical-stage biotech advancing CAR-T programs for difficult-to-treat cancers, with a potential investigator-sponsored MB-109 glioblastoma study targeted for the fourth quarter of 2026. The filing preserves Nasdaq access, but does not solve the underlying problem. Mustang failed to restore its bid price above $1.00 during the initial 180-day window. 〔0〕 Nasdaq has now granted another 180 days, moving the deadline to April 12, 2027. 〔1〕

This is a time extension, not a business milestone. The immediate delisting threat is deferred, giving Mustang more runway while it advances its clinical programs, but the filing contains no new clinical, regulatory, financing, or operating progress. Compliance still requires a $1.00 closing bid for at least 10 consecutive business days.

The likely corporate-action pressure is now explicit. Mustang says it may use a reverse stock split if needed, which could restore the quoted share price without changing the company’s underlying value or advancing its pipeline. 〔2〕 Because the deficiency was already known, the new information is mainly the extra six months—not a reversal of the listing risk.

Bottom line: Nasdaq has bought Mustang Bio time, but the filing confirms rather than removes the listing problem. The company’s clinical story is unchanged; the next meaningful development is whether it can regain compliance organically or must pursue a reverse split before April 12, 2027.

What to watch next

Reverse-split decision or Nasdaq compliance by April 12, 2027

Original filing on SEC EDGAR

Mustang Bio Nasdaq extension buys time as reverse split looms | MBIO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.